Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Jan;28(1):47-49.
doi: 10.1136/ejhpharm-2018-001849. Epub 2019 May 30.

Bullous pemphigoid induced by ustekinumab: a case report

Marta Marin  1 , Natalia Alzueta  2 , Marta Castresana  2 , Ana Gascón  2 , María Pío  2
Affiliations
Case Reports

Bullous pemphigoid induced by ustekinumab: a case report

Marta Marin et al. Eur J Hosp Pharm. 2021 Jan.

Abstract

A possible case of bullous pemphigoid (BP) that developed during treatment with ustekinumab is reported. Ustekinumab is a human monoclonal antibody found in pathologies such as psoriasis, which works by inhibiting the activity of interleukin-12 and interleukin-23. We describe the case of a 75-year-old woman who presented with new onset of erythematous and bullous lesions 5 days after receiving a fifth dose of ustekinumab. The patient was treated with corticosteroids and dapsone, whereupon the lesions disappeared. Ustekinumab was withdrawn. Currently the patient remains asymptomatic. In addition, the histopathological and immunofluorescence findings confirmed the diagnosis of BP. Three causality algorithms were applied and revealed a probable causal relationship. There may be a causal relationship between the use of ustekinumab and BP. This association should be taken into account by physicians when prescribing and reviewing drug therapies.

Keywords: adverse effects; bullous pemphigoid; causality; psoriasis; ustekinumab.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Stavropoulos PG, Soura E, Antoniou C. Drug-induced pemphigoid: a review of the literature. J Eur Acad Dermatol Venereol 2014;28:1133–40. 10.1111/jdv.12366 - DOI - PubMed
    1. Tan CWX, Pang Y, Sim B, et al. . The association between drugs and bullous pemphigoid. Br J Dermatol 2017;176:549–51. 10.1111/bjd.15195 - DOI - PubMed
    1. European Commission . Stelara data-sheet. Available: https://ec.europa.eu/health/documents/communityregister/2016/20160715135... [Accessed 8 Dec 2018].
    1. Naranjo CA, Busto U, Sellers EM, et al. . A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–45. 10.1038/clpt.1981.154 - DOI - PubMed
    1. Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther 1977;21:247–54. 10.1002/cpt1977213247 - DOI - PubMed

Publication types